EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity

Xinyu Wu, Shane M Devine, Margareta Go, Julie V Nguyen, Bernadine G C Lu, Katie Loi, Nathan W Kuchel, Kym N Lowes, Jeffrey P Mitchell, Guillaume Lessene, David Komander, Matthew E Call und 1 weitere

PLOS Pathogens · 2025

DOI: 10.1371/journal.ppat.1013468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Xinyu Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: SARS-CoV-2, Drug Resistance, Viral, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Future Fund, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-escape, where a target evolves to escape inhibition from a drug, has the potential to lead to cross-resistance where drugs that are structurally related or share similar binding mechanisms all become less effective. PLpro inhibitors are currently under development and many emerging PLpro inhibitors are derived from GRL0617, a repurposed SARS-CoV PLpro inhibitor with moderate activity against SARS-CoV-2. Two leading derivatives, PF-07957472 and Jun12682, demonstrate low nanomolar activity and display activity in mice. WEHI-P8 is structurally distinct but binds to a similar pocket adjacent to the active site as GRL0617-like compounds. Using deep mutational scanning, we assessed the potential for PLpro to develop resistance to PF-07957472, Jun12682, and WEHI-P8. PF-07957472 and Jun12682 exhibited largely overlapping escape mutations due to their shared scaffold and binding modes, whereas WEHI-P8 resistance mutations were distinct. These findings underscore the importance of developing structurally diverse inhibitors to minimize resistance risks and ensure that viral mutations against one compound do not compromise the efficacy of others.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Drug Resistance, ViralAntiviral AgentsCOVID-19 Drug TreatmentCoronavirus 3C ProteasesHumansAnimalsCOVID-19MiceMutation

Substanzen

Antiviral AgentsCoronavirus 3C Proteases

Autor:innen und Institutionen

  • The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
  • Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia.
  • Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, Victoria, Australia.

ORCID-Profile: Melissa J Call

Förderung

  • Wellcome Trust
  • Medical Research Future Fund
  • National Health and Medical Research Council

Zitieren

APA

Wu, X., Devine, S. M., Go, M., Nguyen, J. V., Lu, B. G. C., Loi, K., Kuchel, N. W., Lowes, K. N., Mitchell, J. P., Lessene, G., Komander, D., Call, M. E., & Call, M. J. (2025). Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013468

Vancouver

Wu X, Devine SM, Go M, Nguyen JV, Lu BGC, Loi K, et al. Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1013468

BibTeX
@article{Wu2025,
  author = {Wu, Xinyu and Devine, Shane M and Go, Margareta and Nguyen, Julie V and Lu, Bernadine G C and Loi, Katie and Kuchel, Nathan W and Lowes, Kym N and Mitchell, Jeffrey P and Lessene, Guillaume and Komander, David and Call, Matthew E and Call, Melissa J},
  title = {Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity},
  journal = {PLOS Pathogens},
  year = {2025},
  doi = {10.1371/journal.ppat.1013468}
}
Kostenlos starten →